TaKeTiNa in the Treatment of Depression: a Pilot Study.

Sponsor
University of Erlangen-Nürnberg Medical School (Other)
Overall Status
Recruiting
CT.gov ID
NCT05778643
Collaborator
(none)
120
1
2
11.5
10.4

Study Details

Study Description

Brief Summary

The goal of this clinical study's to analyse the impact of TaKeTiNa music therapy in depressed patients.

The main question[s] it aims to answer are:

. Can TaKeTiNa result in a significant pre-to-post intervention decline of depression severity 2. Can TaKeTiNa result in a significantly lower post-intervention depression severity in the T1/T2 group than in the W1/W2 group.

Participants will

  • be randomly assigned to the two groups, intervention vs. waitlist

  • receive either an eight week TaKeTiNa music therapy or waitlist

  • be analysed using questionaires, blood taking, cortisol saliva analysis, measured heart rate variability

Researchers will compare a waitlist to see if TakeTiNa is superior to waitlist

Condition or Disease Intervention/Treatment Phase
  • Behavioral: TaKeTiNa music therapy
N/A

Detailed Description

One third of the depressed patients do not respond adequately to conventional treatment. This seems to be associated with increased production of proinflammatory cytokines such as TNF-a and IL-1, as well as dysregulation of cortisol levels. This project aims to investigate Investigate the effectiveness of TaKeTiNa music therapy in the treatment of patients with clinical diagnosis of moderate to severe depression Investigate the physiological and pathophysiological effects of TaKeTiNa using novel blood based biomarkers of depression, especially LDL cholesterol as well as on immune system function in order to establish immune system based biomarkers for better diagnosis and therapy monitoring of major depressive disorder.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Immunological Mechanisms in the Treatment of Depression and Their Significance in TaKeTiNa Music Therapy as a New Psychotherapeutic Method. A Waitlist-controlled Randomized Group Pilot Study.
Actual Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Feb 14, 2024
Anticipated Study Completion Date :
Feb 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: TaKeTiNa

Participants receive TaKeTiNa Music therapy

Behavioral: TaKeTiNa music therapy
TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.

No Intervention: Waiting

Participants receive no additional therapy

Outcome Measures

Primary Outcome Measures

  1. Comparison of depression severity (HAMD 17) [four month]

    Comparison of depression severity (HAMD 17) in the intervention group from beginning of Therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

Secondary Outcome Measures

  1. Differences in Depression severity (BDI II) [four month]

    Differences in Depression severity in the Intervention Group compared to the Control Group , Assessment through BDI II Questionaire

  2. Differences in anxiety (BAI) [four month]

    Differences in anxiety in the Intervention Group compared to the Control Group and in comparison to pre-intervention , Assessment through BAI Questionaire

  3. Differences in social anxiety [four month]

    Differences in anxiety in the Intervention Group compared to the Control Group and in comparison to pre-intervention , Assessment through social phobia intentory (SPIN), social interaction anxiety scale (SIAS), social phobia scale (SPS)

  4. Differences in enzymes of sphingolipid metabolism [four month]

    Differences in enzymes of sphingolipid metabolism in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  5. Differences in Composition of adaptive cellular immunity [four month]

    Differences in Composition of adaptive cellular immunity in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  6. Differences in Adverse events [four month]

    Differences in Adverse events in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  7. Differences in Mindful Attention and Awareness [four month]

    Differences in MAAS in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  8. Differences in Resilience [four month]

    Differences in RS-25 in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  9. Differences in Physical activity [four month]

    Differences in Physical activity measured by pedometer in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  10. Differences in Heart rate variability [four month]

    Differences in Heart rate variability in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  11. Differences in Cortisol levels [four month]

    Differences in Cortisol levels in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

  12. Differences in serum lipid levels [four month]

    Differences in serum lipid levels in the Intervention Group from beginning of therapy, during the course of therapy, after completion of therapy and after an 8-week follow-up period and in comparison to control group (pre intervention, during intervention, post intervention and after follow up)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Major depressive disorder Ability to walk, speak, and clap

Exclusion Criteria:
  • psychotic symptoms

  • acute suicidality

  • prior intolerance to body therapeutic methods

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Erlangen - Psychiatric Clinic Erlangen Bavaria Germany 91054

Sponsors and Collaborators

  • University of Erlangen-Nürnberg Medical School

Investigators

  • Study Chair: Claudia von Zimmermann, MD, UK Erlangen-Nurnberg

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier:
NCT05778643
Other Study ID Numbers:
  • P066
First Posted:
Mar 21, 2023
Last Update Posted:
Mar 22, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 22, 2023